Diagnostic Utility of Clusterin in Fine Needle Aspiration Biopsy and Core Biopsies of Hepatocellular Carcinoma
Authors:
- 8 April 2025
- journal article
- Published by Wiley in Diagnostic Cytopathology
- Vol. 53 (8) , 363-369
Abstract
Background: Several immunohistochemical markers are available for demonstrating hepatocytic differentiation, thereby confirming the diagnosis of hepatocellular carcinoma (HCC). Clusterin is a new marker of malignant hepatocytes, not evaluated in fine needle aspiration biopsy (FNAB) samples. Hence, we evaluated its diagnostic utility in FNAB cell blocks (CB) and core biopsy samples.Methods: A total of 47 cases of HCC diagnosed on FNAB with CB (41)/core biopsy (6) were retrieved. For comparison, CB from metastatic adenocarcinoma (15) and cases with incidental benign hepatocytes (12) were included. Immunohistochemistry (IHC) for clusterin was performed and the 3 groups were compared to derive its sensitivity and specificity. Canalicular expression was considered positive for hepatocytic differentiation.Results: The cohort comprised 47 cases of HCC, with 43 (91.5%) male and 4 (8.5%) female patients with an age range of 20–78 years. On clusterin IHC, benign hepatocytes showed a track‐like canalicular pattern whereas in HCC, typical enhanced canalicular positivity (3+ intensity) was seen in 32/47 (68%) cases, 17 of which additionally showed cytoplasmic positivity. Only cytoplasmic positivity was noted in 7 HCC cases and was considered negative. All cases of well differentiated (6/6), 67.6% (25/37) of moderately differentiated, and 25% (1/4) of poorly differentiated HCC showed enhanced canalicular positivity, whereas metastatic adenocarcinoma showed cytoplasmic (2/15) or nucleocytoplasmic (1/15) positivity only.Conclusion: IHC for clusterin with enhanced canalicular pattern of expression revealed 68% sensitivity and 100% specificity for HCC, aiding its distinction from metastatic adenocarcinoma and benign hepatocytes in FNAB samples, thereby confirming its diagnostic utility.Keywords
This publication has 22 references indexed in Scilit:
- The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National LevelJAMA Oncology, 2017
- Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the LiverPathology and Oncology Research, 2014
- Role of glypican-3 immunocytochemistry in differentiating hepatocellular carcinoma from metastatic carcinoma of the liver utilizing fine needle aspiration cytologyJournal of the Egyptian National Cancer Institute, 2013
- Utility of an Immunohistochemical Panel Consisting of Glypican-3, Heat-shock Protein-70, and Glutamine Synthetase in the Distinction of Low-grade Hepatocellular Carcinoma From Hepatocellular AdenomaApplied Immunohistochemistry & Molecular Morphology, 2013
- Arginase‐1 is a more sensitive marker of hepatic differentiation than HepPar‐1 and glypican‐3 in fine‐needle aspiration biopsiesCancer Cytopathology, 2012
- Utility of glypican-3 in differentiating hepatocellular carcinoma from other primary and metastatic lesions in FNA of the liver: an immunocytochemical studyLaboratory Investigation, 2008
- Glypican-3 immunocytochemistry in liver fine-needle aspiratesCancer, 2007
- Overexpression of clusterin in human hepatocellular carcinomaHuman Pathology, 2004
- Diagnostic value of HepPar1, pCEA, CD10, and CD34 expression in separating hepatocellular carcinoma from metastatic carcinoma in fine‐needle aspiration cytologyDiagnostic Cytopathology, 2003
- Fine‐needle aspiration biopsy of liver masses: Diagnostic value and reproducibility of cytological criteriaDiagnostic Cytopathology, 2001